3.8 Article

Pathophysiology of osteoporosis

Journal

WIENER MEDIZINISCHE WOCHENSCHRIFT
Volume 159, Issue 9-10, Pages 230-234

Publisher

SPRINGER WIEN
DOI: 10.1007/s10354-009-0647-y

Keywords

Osteoporosis; bone remodeling; osteoblasts; osteoclasts; osteoimmunology; pig

Funding

  1. Amgen GmbH
  2. Eli Lilly GmbH
  3. MSD Merck Sharp Dohme GesmbH
  4. Nycomed Pharma
  5. Roche Austria
  6. Servier Austria
  7. Sanofi Aventis

Ask authors/readers for more resources

Osteoporosis is a classical age-related disease that affects women more often than men. The hypothesis that osteoporosis is a consequence of estrogen deficiency, has been proposed as early as 1941 by Albright and colleagues [1]. The exact mechanisms of this steroid hormone deficiency in postmenopausal women as well as in the elderly men are continuously being unraveled. Collectively, estrogen deficiency has direct as well as indirect impacts on bone metabolism all of which promote osteoclastogenesis. This review aims at shedding light on the endocrine and osteoimmunological mechanisms that lead to involutional osteoporosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available